PortalPublikationenCurrent Applications and Future Development of Magnetic Reso...

Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer

Standard

Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer. / Ding, Hao; Velasco, Carlos; Ye, Huihui; Lindner, Thomas; Grech-Sollars, Matthew; O'Callaghan, James; Hiley, Crispin; Chouhan, Manil D; Niendorf, Thoralf; Koh, Dow-Mu; Prieto, Claudia; Adeleke, Sola.

in: CANCERS, Jahrgang 13, Nr. 19, 4742, 22.09.2021.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Ding, H, Velasco, C, Ye, H, Lindner, T, Grech-Sollars, M, O'Callaghan, J, Hiley, C, Chouhan, MD, Niendorf, T, Koh, D-M, Prieto, C & Adeleke, S 2021, 'Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer', CANCERS, Jg. 13, Nr. 19, 4742. https://doi.org/10.3390/cancers13194742

APA

Ding, H., Velasco, C., Ye, H., Lindner, T., Grech-Sollars, M., O'Callaghan, J., Hiley, C., Chouhan, M. D., Niendorf, T., Koh, D-M., Prieto, C., & Adeleke, S. (2021). Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer. CANCERS, 13(19), [4742]. https://doi.org/10.3390/cancers13194742

Vancouver

Ding H, Velasco C, Ye H, Lindner T, Grech-Sollars M, O'Callaghan J et al. Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer. CANCERS. 2021 Sep 22;13(19). 4742. https://doi.org/10.3390/cancers13194742

Bibtex

@article{055800d8be2f46b8a7a9d247c5bf6e7d,
title = "Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer",
abstract = "Magnetic resonance imaging (MRI) has enabled non-invasive cancer diagnosis, monitoring, and management in common clinical settings. However, inadequate quantitative analyses in MRI continue to limit its full potential and these often have an impact on clinicians' judgments. Magnetic resonance fingerprinting (MRF) has recently been introduced to acquire multiple quantitative parameters simultaneously in a reasonable timeframe. Initial retrospective studies have demonstrated the feasibility of using MRF for various cancer characterizations. Further trials with larger cohorts are still needed to explore the repeatability and reproducibility of the data acquired by MRF. At the moment, technical difficulties such as undesirable processing time or lack of motion robustness are limiting further implementations of MRF in clinical oncology. This review summarises the latest findings and technology developments for the use of MRF in cancer management and suggests possible future implications of MRF in characterizing tumour heterogeneity and response assessment.",
author = "Hao Ding and Carlos Velasco and Huihui Ye and Thomas Lindner and Matthew Grech-Sollars and James O'Callaghan and Crispin Hiley and Chouhan, {Manil D} and Thoralf Niendorf and Dow-Mu Koh and Claudia Prieto and Sola Adeleke",
year = "2021",
month = sep,
day = "22",
doi = "10.3390/cancers13194742",
language = "English",
volume = "13",
journal = "CANCERS",
issn = "2072-6694",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "19",

}

RIS

TY - JOUR

T1 - Current Applications and Future Development of Magnetic Resonance Fingerprinting in Diagnosis, Characterization, and Response Monitoring in Cancer

AU - Ding, Hao

AU - Velasco, Carlos

AU - Ye, Huihui

AU - Lindner, Thomas

AU - Grech-Sollars, Matthew

AU - O'Callaghan, James

AU - Hiley, Crispin

AU - Chouhan, Manil D

AU - Niendorf, Thoralf

AU - Koh, Dow-Mu

AU - Prieto, Claudia

AU - Adeleke, Sola

PY - 2021/9/22

Y1 - 2021/9/22

N2 - Magnetic resonance imaging (MRI) has enabled non-invasive cancer diagnosis, monitoring, and management in common clinical settings. However, inadequate quantitative analyses in MRI continue to limit its full potential and these often have an impact on clinicians' judgments. Magnetic resonance fingerprinting (MRF) has recently been introduced to acquire multiple quantitative parameters simultaneously in a reasonable timeframe. Initial retrospective studies have demonstrated the feasibility of using MRF for various cancer characterizations. Further trials with larger cohorts are still needed to explore the repeatability and reproducibility of the data acquired by MRF. At the moment, technical difficulties such as undesirable processing time or lack of motion robustness are limiting further implementations of MRF in clinical oncology. This review summarises the latest findings and technology developments for the use of MRF in cancer management and suggests possible future implications of MRF in characterizing tumour heterogeneity and response assessment.

AB - Magnetic resonance imaging (MRI) has enabled non-invasive cancer diagnosis, monitoring, and management in common clinical settings. However, inadequate quantitative analyses in MRI continue to limit its full potential and these often have an impact on clinicians' judgments. Magnetic resonance fingerprinting (MRF) has recently been introduced to acquire multiple quantitative parameters simultaneously in a reasonable timeframe. Initial retrospective studies have demonstrated the feasibility of using MRF for various cancer characterizations. Further trials with larger cohorts are still needed to explore the repeatability and reproducibility of the data acquired by MRF. At the moment, technical difficulties such as undesirable processing time or lack of motion robustness are limiting further implementations of MRF in clinical oncology. This review summarises the latest findings and technology developments for the use of MRF in cancer management and suggests possible future implications of MRF in characterizing tumour heterogeneity and response assessment.

U2 - 10.3390/cancers13194742

DO - 10.3390/cancers13194742

M3 - SCORING: Review article

C2 - 34638229

VL - 13

JO - CANCERS

JF - CANCERS

SN - 2072-6694

IS - 19

M1 - 4742

ER -